These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24395436)

  • 21.
    Dreisig K; Brünner ED; Marquart HV; Helt LR; Nersting J; Frandsen TL; Jonsson OG; Taskinen M; Vaitkeviciene G; Lund B; Abrahamsson J; Lepik K; Schmiegelow K
    Pediatr Hematol Oncol; 2021 Apr; 38(3):227-238. PubMed ID: 33205673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.
    Karas-Kuzelicki N; Mlinaric-Rascan I
    Pharmacogenomics; 2009 Aug; 10(8):1309-22. PubMed ID: 19663675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
    Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
    J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
    Tolar J; Bostrom BC; La MK; Sather HN
    Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
    Borgmann A; Zinn C; Hartmann R; Herold R; Kaatsch P; Escherich G; Möricke A; Henze G; von Stackelberg A;
    Eur J Cancer; 2008 Jan; 44(2):257-68. PubMed ID: 17981026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
    Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
    J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism.
    Bo J; Schrøder H; Kristinsson J; Madsen B; Szumlanski C; Weinshilboum R; Andersen JB; Schmiegelow K
    Cancer; 1999 Sep; 86(6):1080-6. PubMed ID: 10491537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse.
    Schmiegelow K; Heyman M; Gustafsson G; Lausen B; Wesenberg F; Kristinsson J; Vettenranta K; Schroeder H; Forestier E; Rosthoej S;
    Leukemia; 2010 Apr; 24(4):715-20. PubMed ID: 20130603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
    Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
    Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia.
    Bohnstedt C; Levinsen M; Rosthøj S; Zeller B; Taskinen M; Hafsteinsdottir S; Björgvinsdóttir H; Heyman M; Schmiegelow K;
    Leukemia; 2013 Apr; 27(4):866-70. PubMed ID: 23138181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
    Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia.
    Wennerstrand P; Mårtensson LG; Söderhäll S; Zimdahl A; Appell ML
    Eur J Clin Pharmacol; 2013 Sep; 69(9):1641-9. PubMed ID: 23660772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thiopurine S-methyltransferase (TPMT) gene polymorphism in Brazilian children with acute lymphoblastic leukemia: association with clinical and laboratory data.
    Silva MR; de Oliveira BM; Viana MB; Murao M; Romanha AJ
    Ther Drug Monit; 2008 Dec; 30(6):700-4. PubMed ID: 19057372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
    Stanulla M; Schaeffeler E; Möricke A; Coulthard SA; Cario G; Schrauder A; Kaatsch P; Dördelmann M; Welte K; Zimmermann M; Reiter A; Eichelbaum M; Riehm H; Schrappe M; Schwab M
    Blood; 2009 Aug; 114(7):1314-8. PubMed ID: 19535798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
    Fakhoury M; Andreu-Gallien J; Mahr A; Medard Y; Azougagh S; Vilmer E; Jacqz-Aigrain E
    J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.
    Andersen JB; Szumlanski C; Weinshilboum RM; Schmiegelow K
    Acta Paediatr; 1998 Jan; 87(1):108-11. PubMed ID: 9510461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thiopurine methyltransferase in acute lymphoblastic leukaemia: biochemical and molecular biological aspects.
    Brouwer C; De Abreu RA; Keizer-Garritsen JJ; Lambooy LH; Ament K; ter Riet PG; van Wering ER; Trijbels FJ; Veerman AJ; Hoogerbrugge PM; Bökkerink JP
    Eur J Cancer; 2005 Mar; 41(4):613-23. PubMed ID: 15737567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
    J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.
    Bhatia S; Landier W; Hageman L; Chen Y; Kim H; Sun CL; Kornegay N; Evans WE; Angiolillo AL; Bostrom B; Casillas J; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Wong FL; Relling MV
    JAMA Oncol; 2015 Jun; 1(3):287-95. PubMed ID: 26181173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
    Stocco G; Crews KR; Evans WE
    Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.